JP2019510079A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510079A5 JP2019510079A5 JP2018563946A JP2018563946A JP2019510079A5 JP 2019510079 A5 JP2019510079 A5 JP 2019510079A5 JP 2018563946 A JP2018563946 A JP 2018563946A JP 2018563946 A JP2018563946 A JP 2018563946A JP 2019510079 A5 JP2019510079 A5 JP 2019510079A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- use according
- disease
- disorder
- vasoconstriction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 206010047139 Vasoconstriction Diseases 0.000 claims 7
- 230000025033 vasoconstriction Effects 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010056340 Diabetic ulcer Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1603311.0 | 2016-02-25 | ||
| GBGB1603311.0A GB201603311D0 (en) | 2016-02-25 | 2016-02-25 | New uses and methods |
| PCT/GB2017/050498 WO2017144909A1 (en) | 2016-02-25 | 2017-02-24 | Methods of treating diseases characterised by vasoconstriction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510079A JP2019510079A (ja) | 2019-04-11 |
| JP2019510079A5 true JP2019510079A5 (enExample) | 2020-04-02 |
Family
ID=55806947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563946A Pending JP2019510079A (ja) | 2016-02-25 | 2017-02-24 | 血管収縮を特徴とする疾患を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190038603A1 (enExample) |
| EP (1) | EP3419620A1 (enExample) |
| JP (1) | JP2019510079A (enExample) |
| CN (1) | CN109069487A (enExample) |
| AU (1) | AU2017222406B2 (enExample) |
| CA (1) | CA3014728A1 (enExample) |
| GB (1) | GB201603311D0 (enExample) |
| RU (1) | RU2018133818A (enExample) |
| WO (1) | WO2017144909A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE070649T2 (hu) | 2017-10-19 | 2025-06-28 | Teijin Pharma Ltd | Benzimidazol-származékok és felhasználásuk |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876930A4 (en) | 2018-11-07 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| KR20210059663A (ko) * | 2019-11-15 | 2021-05-25 | 가천대학교 산학협력단 | 신규한 벤즈이미다졸 유도체 및 이의 용도 |
| BR112022022409A2 (pt) | 2020-05-06 | 2023-02-07 | Ajax Therapeutics Inc | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 |
| WO2022140527A1 (en) | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| US20250340557A1 (en) * | 2022-07-06 | 2025-11-06 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| GB202212749D0 (en) | 2022-09-01 | 2022-10-19 | Gesynta Pharma Ab | New uses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2207547A4 (en) * | 2007-10-05 | 2010-11-17 | Amira Pharmaceuticals Inc | PROTEIN INHIBITORS THAT ACTIVATE 5-LIPOXYGENASE |
| UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011023812A1 (en) * | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| US8759537B2 (en) * | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| EP2495244A1 (en) * | 2011-03-02 | 2012-09-05 | NovaSaid AB | Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors |
| SI2746265T1 (sl) * | 2011-08-18 | 2016-03-31 | Nippon Shinyaku Co., Ltd. | Heterociklični derivat kot zaviralec mikrosomske prostaglandin-e sintaze (mpges) |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| MX368504B (es) * | 2014-04-14 | 2019-10-04 | Shanghai hengrui pharmaceutical co ltd | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. |
-
2016
- 2016-02-25 GB GBGB1603311.0A patent/GB201603311D0/en not_active Ceased
-
2017
- 2017-02-24 WO PCT/GB2017/050498 patent/WO2017144909A1/en not_active Ceased
- 2017-02-24 CA CA3014728A patent/CA3014728A1/en active Pending
- 2017-02-24 US US16/079,203 patent/US20190038603A1/en not_active Abandoned
- 2017-02-24 JP JP2018563946A patent/JP2019510079A/ja active Pending
- 2017-02-24 AU AU2017222406A patent/AU2017222406B2/en not_active Ceased
- 2017-02-24 CN CN201780012516.XA patent/CN109069487A/zh active Pending
- 2017-02-24 EP EP17713372.5A patent/EP3419620A1/en not_active Withdrawn
- 2017-02-24 RU RU2018133818A patent/RU2018133818A/ru unknown
-
2022
- 2022-01-05 US US17/569,049 patent/US20220218670A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018133818A (ru) | Способы лечения заболеваний, характеризующихся вазоконстрикцией | |
| JP2021509912A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2017149726A5 (enExample) | ||
| JP2016106149A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2015083580A5 (enExample) | ||
| CN111836807A (zh) | 氧杂螺环类化合物及其制备方法和用途 | |
| JP2015516427A5 (enExample) | ||
| JP2017533930A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2018537535A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2021529829A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2015526455A5 (enExample) | ||
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| JP2016527312A5 (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物 | |
| JP2020510045A5 (enExample) |